Furthermore, findings of CSF p-tau at threonine 217 (p-tau217), which suggests stronger associations with AD pathology than standard CSF p-tau181 biomarkers [6, 26, 28], have also been replicated in plasma [38, 48]. Here, MAPT is linked to Alzheimer disease.